Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
BRAF V600 Mutations in Solid Tumors Market: By Tumor Type, Non-Small Cell Lung Cancer, and Others), Diagnostic Method, Immunohistochemistry, and Polymerase Chain Reaction ), Treatment Type, and Geography and Forecast to 2030
BRAF V600 Mutations in Solid Tumors Market size was valued at US$ X million in 2023 and is poised to grow at a CAGR of x% from 2024 - 2030. The BRAF V600 Mutations in Solid Tumors market is a battlefield of innovation, aiming to combat tumors harboring this specific genetic alteration. Advancements in diagnostic tools like next-generation sequencing (NGS) enable more accurate and comprehensive detection of BRAF V600 mutations, leading to earlier identification and treatment initiation. Also, increased educational efforts aimed at both healthcare professionals and the public regarding BRAF mutations are raising awareness of these genetic alterations and the availability of targeted therapies. In addition, the growing emphasis on precision medicine, tailoring treatments to a patient's specific genetic makeup, highlights the importance of BRAF V600 mutation testing for determining the most effective course of therapy. BRAF inhibitor drugs and combination therapies specifically target the BRAF protein with the V600 mutation, demonstrating improved efficacy compared to traditional therapies in many cases. Ongoing clinical trials for new BRAF inhibitor drugs and combination therapies with different mechanisms of action are yielding promising results, offering hope for even more effective treatments in the future.
Moreover, targeted therapies can offer a less toxic and debilitating treatment experience compared to traditional therapies like chemotherapy, potentially improving patient quality of life. As the cost of NGS decreases and its availability increases, it is becoming a more widely used diagnostic tool, leading to the identification of more BRAF V600 mutation-positive tumors and driving market growth. Furthermore, the healthcare sector is shifting towards a value-based care model, where reimbursement is tied to patient outcomes. This incentivizes the use of targeted therapies that demonstrate improved efficacy and survival rates. Also, regulatory bodies are increasingly approving BRAF inhibitor drugs and combination therapies based on robust clinical data. Additionally, reimbursement pathways are being established to ensure patient access to these potentially life-saving treatments. However, BRAF inhibitor drugs and combination therapies are often very expensive, creating a significant financial burden for patients and healthcare systems. This can limit patient access to these potentially life-saving treatments.
Recent Market Developments:
Study Period
2024 - 2030Base Year
2023CAGR
x%Largest Market
North AmericaFastest Growing Market
Asia pacific
BRAF V600 mutations are present in a significant percentage of various cancers, and there remains a significant unmet medical need for effective treatments, particularly for patients who do not respond well to traditional therapies. In addition, targeted therapies offer the potential for improved patient outcomes, including increased progression-free survival rates and overall survival rates. This translates to a longer lifespan and better quality of life for patients with BRAF V600 mutation-positive tumors which propels the market expansion. Moreover, the significant potential of BRAF inhibitor drugs and combination therapies is attracting continued investment in research and development. This fuels the discovery of new drugs, improved treatment regimens, and a deeper understanding of BRAF mutations further drives the market growth.
Report Benchmarks |
Details |
Report Study Period |
2024 - 2030 |
Market CAGR |
x% |
Tumor Type |
|
By Diagnostic Method |
|
By Treatment Type |
|
Download Free Sample Report
The Asia Pacific is the fastest growing region in the BRAF V600 Mutations in Solid Tumors Market.
The North America dominates the BRAF V600 Mutations in Solid Tumors market.
The leading players in the BRAF V600 Mutations in Solid Tumors Market are Roche, Pfizer, Bayer, Novartis, Exelixis, AstraZeneca, Daiichi Sankyo, Debiopharm Group, Bristol-Myers Squibb, and Eli Lilly and Company.
Historic years considered for the market study are 2019 to 2022, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.
1. Executive Summary |
2. Global BRAF V600 Mutations in Solid Tumors Market Introduction |
2.1. Global BRAF V600 Mutations in Solid Tumors Market - Taxonomy |
2.2. Global BRAF V600 Mutations in Solid Tumors Market - Definitions |
2.2.1. Tumor Type |
2.2.2. Treatment Method |
2.2.3. BRAF Mutation Status |
2.2.4. End-User |
2.2.5. Region |
3. Global BRAF V600 Mutations in Solid Tumors Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Key Developments |
4. Global BRAF V600 Mutations in Solid Tumors Market By Tumor Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
4.1. Melanoma |
4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3. Market Opportunity Analysis |
4.2. Colorectal Cancer |
4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3. Market Opportunity Analysis |
4.3. Lung Cancer |
4.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
4.4. Thyroid Cancer |
4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.4.3. Market Opportunity Analysis |
4.5. Other Solid Tumor Types |
4.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.5.3. Market Opportunity Analysis |
5. Global BRAF V600 Mutations in Solid Tumors Market By Treatment Method, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Targeted Therapies |
5 1 1 Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Chemotherapy |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Immunotherapy |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Combination Therapies |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Surgery |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Radiation Therapy |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global BRAF V600 Mutations in Solid Tumors Market By BRAF Mutation Status, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. BRAF V600E |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. BRAF V600K |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Other BRAF Mutations |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global BRAF V600 Mutations in Solid Tumors Market By End-User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Cancer Treatment Centers |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Clinics |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Research Institutions |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global BRAF V600 Mutations in Solid Tumors Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. MEA |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global BRAF V600 Mutations in Solid Tumors Market - Opportunity Analysis Index, By Treatment Method, Tumor Type, BRAF Mutation Status, End-User, , , , and Region, 2024 - 2030 |
9. North America BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Melanoma |
9.1.2. Colorectal Cancer |
9.1.3. Lung Cancer |
9.1.4. Thyroid Cancer |
9.1.5. Other Solid Tumor Types |
9.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Targeted Therapies |
9.2.2. Chemotherapy |
9.2.3. Immunotherapy |
9.2.4. Combination Therapies |
9.2.5. Surgery |
9.2.6. Radiation Therapy |
9.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1. BRAF V600E |
9.3.2. BRAF V600K |
9.3.3. Other BRAF Mutations |
9.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1. Hospitals |
9.4.2. Cancer Treatment Centers |
9.4.3. Clinics |
9.4.4. Research Institutions |
9.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.5.1. USA |
9.5.2. Canada |
10. Europe BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Melanoma |
10.1.2. Colorectal Cancer |
10.1.3. Lung Cancer |
10.1.4. Thyroid Cancer |
10.1.5. Other Solid Tumor Types |
10.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Targeted Therapies |
10.2.2. Chemotherapy |
10.2.3. Immunotherapy |
10.2.4. Combination Therapies |
10.2.5. Surgery |
10.2.6. Radiation Therapy |
10.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. BRAF V600E |
10.3.2. BRAF V600K |
10.3.3. Other BRAF Mutations |
10.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Hospitals |
10.4.2. Cancer Treatment Centers |
10.4.3. Clinics |
10.4.4. Research Institutions |
10.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1. Germany |
10.5.2. France |
10.5.3. Italy |
10.5.4. Spain |
10.5.5. UK |
10.5.6. Rest of Europe |
11. Asia Pacific BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Melanoma |
11.1.2. Colorectal Cancer |
11.1.3. Lung Cancer |
11.1.4. Thyroid Cancer |
11.1.5. Other Solid Tumor Types |
11.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Targeted Therapies |
11.2.2. Chemotherapy |
11.2.3. Immunotherapy |
11.2.4. Combination Therapies |
11.2.5. Surgery |
11.2.6. Radiation Therapy |
11.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. BRAF V600E |
11.3.2. BRAF V600K |
11.3.3. Other BRAF Mutations |
11.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Hospitals |
11.4.2. Cancer Treatment Centers |
11.4.3. Clinics |
11.4.4. Research Institutions |
11.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1. China |
11.5.2. Japan |
11.5.3. South Korea |
11.5.4. India |
11.5.5. Rest of APAC |
12. Latin America BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Melanoma |
12.1.2. Colorectal Cancer |
12.1.3. Lung Cancer |
12.1.4. Thyroid Cancer |
12.1.5. Other Solid Tumor Types |
12.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Targeted Therapies |
12.2.2. Chemotherapy |
12.2.3. Immunotherapy |
12.2.4. Combination Therapies |
12.2.5. Surgery |
12.2.6. Radiation Therapy |
12.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1. BRAF V600E |
12.3.2. BRAF V600K |
12.3.3. Other BRAF Mutations |
12.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Hospitals |
12.4.2. Cancer Treatment Centers |
12.4.3. Clinics |
12.4.4. Research Institutions |
12.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1. Brazil |
12.5.2. Mexico |
12.5.3. Argentina |
12.5.4. Rest of Latin America |
13. MEA BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Melanoma |
13.1.2. Colorectal Cancer |
13.1.3. Lung Cancer |
13.1.4. Thyroid Cancer |
13.1.5. Other Solid Tumor Types |
13.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Targeted Therapies |
13.2.2. Chemotherapy |
13.2.3. Immunotherapy |
13.2.4. Combination Therapies |
13.2.5. Surgery |
13.2.6. Radiation Therapy |
13.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1. BRAF V600E |
13.3.2. BRAF V600K |
13.3.3. Other BRAF Mutations |
13.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Hospitals |
13.4.2. Cancer Treatment Centers |
13.4.3. Clinics |
13.4.4. Research Institutions |
13.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1. GCC Countries |
13.5.2. South Africa |
13.5.3. Rest of MEA |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Roche |
14.2.2. Pfizer |
14.2.3. Novartis |
14.2.4. Bristol-Myers Squibb |
14.2.5. Eli Lilly and Company |
14.2.6. Debiopharm Group |
14.2.7. Bayer |
14.2.8. AstraZeneca |
14.2.9. Exelixis |
14.2.10. Daiichi Sankyo |
15. Research Methodology |
16. Key Assumptions and Acronyms |
Key Market Players